id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1998-D-0021-0008,FDA,FDA-1998-D-0021,ANDAs: Impurities in Drug Substances- Guidance for Industry,Other,Guidance,2009-07-15T04:00:00Z,2009,7,2009-07-15T04:00:00Z,,2020-05-12T17:05:58Z,,0,0,09000064809f1f49
FDA-1998-D-0021-0006,FDA,FDA-1998-D-0021,SEE FDA-1998-D-0021-0007,Notice,NAD-Notice of Availability of Data,2009-07-15T04:00:00Z,2009,7,2009-07-15T04:00:00Z,,2009-07-15T16:49:49Z,E9-16868,0,0,09000064809f1cd4
FDA-1998-D-0021-0007,FDA,FDA-1998-D-0021,Guidance for Industry on Abbreviated New Drug Applications: Impurities in Drug Substances; Availability,Notice,Notice of Availability,2009-07-15T04:00:00Z,2009,7,2009-07-15T04:00:00Z,,2020-05-12T17:04:06Z,E9-16868,0,0,09000064809f1620